Related Experiment Video
Updated: May 2, 2026

Three-Dimensional Culture Assay to Explore Cancer Cell Invasiveness and Satellite Tumor Formation
Published on: August 18, 2016
Advanced cancer patients' knowledge and opinions regarding the French law on advance directives: a multicenter
Adrien Evin1,2, Guillaume Economos3, Damien Hugues4
1Nantes Université, CHU de Nantes, Service de soins palliatifs et de support, F-44000, Nantes, France. adrien.evin@chu-nantes.fr.
Purpose:
Advance directives (AD) are a key tool within advance care planning (ACP), intended to support patient autonomy and guide end-of-life care. Despite their legal recognition in France, their use in the general population remains limited. Moreover, data on AD use among patients with advanced cancer, a population particularly concerned by end-of-life decisions, remain scarce. This study aimed to assess the knowledge and opinions regarding AD among patients with advanced cancer in France who were receiving specialized palliative care.
Methods:
Between 2016 and 2020, we conducted a multicenter cross-sectional study across 14 palliative care departments in France. Patients with advanced cancer completed a standardized questionnaire assessing their awareness, use, and perceptions of AD, along with sociodemographic and clinical characteristics.
Results:
A total of 331 patients were included. Among them, 53.5% were aware of AD, and 23.6% had completed one. Overall, 72.2% of patients supported legally binding AD, and 66% opposed fixed expiration dates; among those favoring time limits, most chose 1-3 years. In multivariable analysis, a higher educational level and prior treatment during the curable phase were independently associated with knowledge of AD, while completion was associated with older age, higher education, and the absence of ongoing cancer treatment. A higher educational level was also associated with favoring legally binding AD.
Conclusion:
French rates of AD completion remain modest. Our findings highlight the need for personalized, repeated discussions about end-of-life preferences and for enhanced clinician training in ACP. AD should be approached as a flexible tool within broader patient-centered discussions.
Clinical Trials Identifier:
NCT03664856.
More Related Videos
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Cancer Survival Analysis

